Intercept Pharmaceuticals, Inc.
ICPT
ICPT was delisted on the 7th of November, 2023.
147 hedge funds and large institutions have $1.21B invested in Intercept Pharmaceuticals, Inc. in 2018 Q1 according to their latest regulatory filings, with 18 funds opening new positions, 59 increasing their positions, 42 reducing their positions, and 37 closing their positions.
40% more repeat investments, than reductions
Existing positions increased: 59 | Existing positions reduced: 42
14% more call options, than puts
Call options by funds: $59.9M | Put options by funds: $52.5M
12% more capital invested
Capital invested by funds: $1.08B → $1.21B (+$127M)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
13% less funds holding
Funds holding: 168 → 147 (-21)
51% less first-time investments, than exits
New positions opened: 18 | Existing positions closed: 37
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Sarissa Capital Management
Greenwich,
Connecticut
|
+$27.3M |
| 2 |
ECP
Elk Creek Partners
Denver,
Colorado
|
+$21M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
+$15.3M |
| 4 |
First Trust Advisors
Wheaton,
Illinois
|
+$12.8M |
| 5 |
SM
Senvest Management
New York
|
+$10.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$23.9M |
| 2 |
JP Morgan Chase
New York
|
-$17.7M |
| 3 |
EA
Emerald Advisers
Leola,
Pennsylvania
|
-$9.5M |
| 4 |
EMFAT
Emerald Mutual Fund Advisers Trust
Leola,
Pennsylvania
|
-$6.76M |
| 5 |
Two Sigma Investments
New York
|
-$5.98M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
TG
176
TLP Group
Evanston,
Illinois
| – | -$7K | -113 | Closed |
|
|
AWMS
177
Advocacy Wealth Management Services
Atlanta,
Georgia
| – | -$6K | -100 | Closed |
|
|
VIA
178
Vantage Investment Advisors
State College,
Pennsylvania
| – | -$4K | -61 | Closed |
|
179
Russell Investments Group
London,
United Kingdom
| – | -$2K | -30 | Closed |
|
180
Carson Wealth (CWM LLC)
Omaha,
Nebraska
| – | -$1K | -23 | Closed |
|
ICPT Hedge Fund Activity: Q1 2018 in Review
147 of the 4,363 institutional investors tracked by Wall St. Rank reported a position in Intercept Pharmaceuticals, Inc. (ICPT) for Q1 2018, worth a combined $1.21B — up 12% from $1.08B a quarter earlier.
Sellers outnumbered buyers: 37 funds closed out of ICPT and 18 opened new positions — a net loss of 19 holders — while 42 trimmed existing stakes and 59 added.
The largest buyer was Sarissa Capital Management, adding an estimated $27.3M. The largest seller was Morgan Stanley, cutting an estimated $23.9M.
- 147 institutional investors held Intercept Pharmaceuticals, Inc. (ICPT) as of Q1 2018, down from 168 in Q4 2017.
- Funds reported $1.21B of Intercept Pharmaceuticals, Inc. stock for Q1 2018, up 12% quarter-over-quarter.
- 18 funds opened new Intercept Pharmaceuticals, Inc. positions in Q1 2018 and 37 closed out, a net change of -19 holders.
- The largest Intercept Pharmaceuticals, Inc. buyer in Q1 2018 was Sarissa Capital Management, an estimated $27.3M added.
- The largest Intercept Pharmaceuticals, Inc. seller in Q1 2018 was Morgan Stanley, an estimated $23.9M sold.
Based on aggregated 13F filings for Q1 2018.